ID   TYPH_HUMAN              Reviewed;         482 AA.
AC   P19971; A8MW15; H9KVA0; Q13390; Q8WVB7;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=Thymidine phosphorylase;
DE            Short=TP;
DE            EC=2.4.2.4;
DE   AltName: Full=Gliostatin;
DE   AltName: Full=Platelet-derived endothelial cell growth factor;
DE            Short=PD-ECGF;
DE   AltName: Full=TdRPase;
DE   Flags: Precursor;
GN   Name=TYMP; Synonyms=ECGF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANT LEU-471.
RC   TISSUE=Placenta;
RX   PubMed=2467210; DOI=10.1038/338557a0;
RA   Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C.,
RA   Hagiwara K., Usuki K., Takaku F., Risau W., Heldin C.-H.;
RT   "Identification of angiogenic activity and the cloning and expression
RT   of platelet-derived endothelial cell growth factor.";
RL   Nature 338:557-562(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1580101; DOI=10.1002/yea.320080106;
RA   Finnis C., Goodey A., Courtney M., Sleep D.;
RT   "Expression of recombinant platelet-derived endothelial cell growth
RT   factor in the yeast Saccharomyces cerevisiae.";
RL   Yeast 8:57-60(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Dermoid cancer;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-471.
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 149-244, AND PROTEIN SEQUENCE OF 125-178 AND
RP   236-244.
RX   PubMed=1570012; DOI=10.1038/356668a0;
RA   Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S.,
RA   Fukui K., Yamada Y.;
RT   "Angiogenic factor.";
RL   Nature 356:668-668(1992).
RN   [7]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=1400349;
RA   Asai K., Nakanishi K., Isobe I., Eksioglu Y.Z., Hirano A., Hama K.,
RA   Miyamoto T., Kato T.;
RT   "Neurotrophic action of gliostatin on cortical neurons. Identity of
RT   gliostatin and platelet-derived endothelial cell growth factor.";
RL   J. Biol. Chem. 267:20311-20316(1992).
RN   [8]
RP   FUNCTION.
RX   PubMed=1590793; DOI=10.1016/S0006-291X(05)80025-7;
RA   Usuki K., Saras J., Waltenberger J., Miyazono K., Pierce G.,
RA   Thomason A., Heldin C.-H.;
RT   "Platelet-derived endothelial cell growth factor has thymidine
RT   phosphorylase activity.";
RL   Biochem. Biophys. Res. Commun. 184:1311-1316(1992).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 12-482 IN COMPLEX WITH
RP   INHIBITOR, AND SUBUNIT.
RX   PubMed=14725767; DOI=10.1016/j.str.2003.11.018;
RA   Norman R.A., Barry S.T., Bate M., Breed J., Colls J.G., Ernill R.J.,
RA   Luke R.W., Minshull C.A., McAlister M.S., McCall E.J., McMiken H.H.,
RA   Paterson D.S., Timms D., Tucker J.A., Pauptit R.A.;
RT   "Crystal structure of human thymidine phosphorylase in complex with a
RT   small molecule inhibitor.";
RL   Structure 12:75-84(2004).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS), AND SUBUNIT.
RX   PubMed=16803458; DOI=10.1042/BJ20060513;
RA   El Omari K., Bronckaers A., Liekens S., Perez-Perez M.J.,
RA   Balzarini J., Stammers D.K.;
RT   "Structural basis for non-competitive product inhibition in human
RT   thymidine phosphorylase: implications for drug design.";
RL   Biochem. J. 399:199-204(2006).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) ALONE AND IN COMPLEX WITH
RP   5-IODOURACIL, SUBSTRATE-BINDING SITES, AND MUTAGENESIS OF TYR-199.
RX   PubMed=19555658; DOI=10.1016/j.bbrc.2009.06.104;
RA   Mitsiki E., Papageorgiou A.C., Iyer S., Thiyagarajan N., Prior S.H.,
RA   Sleep D., Finnis C., Acharya K.R.;
RT   "Structures of native human thymidine phosphorylase and in complex
RT   with 5-iodouracil.";
RL   Biochem. Biophys. Res. Commun. 386:666-670(2009).
RN   [14]
RP   VARIANTS MTDPS1 ARG-145; SER-153; ARG-222; ALA-289 AND 397-LEU-ALA-398
RP   DEL.
RX   PubMed=9924029; DOI=10.1126/science.283.5402.689;
RA   Nishino I., Spinazzola A., Hirano M.;
RT   "Thymidine phosphorylase gene mutations in MNGIE, a human
RT   mitochondrial disorder.";
RL   Science 283:689-692(1999).
RN   [15]
RP   VARIANT MTDPS1 GLN-44.
RX   PubMed=12177387; DOI=10.1212/WNL.59.3.455;
RA   Gamez J., Ferreiro C., Accarino M.L., Guarner L., Tadesse S.,
RA   Marti R.A., Andreu A.L., Raguer N., Cervera C., Hirano M.;
RT   "Phenotypic variability in a Spanish family with MNGIE.";
RL   Neurology 59:455-457(2002).
CC   -!- FUNCTION: May have a role in maintaining the integrity of the
CC       blood vessels. Has growth promoting activity on endothelial cells,
CC       angiogenic activity in vivo and chemotactic activity on
CC       endothelial cells in vitro. {ECO:0000269|PubMed:1590793}.
CC   -!- FUNCTION: Catalyzes the reversible phosphorolysis of thymidine.
CC       The produced molecules are then utilized as carbon and energy
CC       sources or in the rescue of pyrimidine bases for nucleotide
CC       synthesis. {ECO:0000269|PubMed:1590793}.
CC   -!- CATALYTIC ACTIVITY: Thymidine + phosphate = thymine + 2-deoxy-
CC       alpha-D-ribose 1-phosphate.
CC   -!- PATHWAY: Pyrimidine metabolism; dTMP biosynthesis via salvage
CC       pathway; dTMP from thymine: step 1/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:14725767,
CC       ECO:0000269|PubMed:16803458, ECO:0000269|PubMed:19555658}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19971-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19971-2; Sequence=VSP_045556;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Mitochondrial DNA depletion syndrome 1, MNGIE type
CC       (MTDPS1) [MIM:603041]: A multisystem disease associated with
CC       mitochondrial dysfunction. It is clinically characterized by onset
CC       between the second and fifth decades of life, ptosis, progressive
CC       external ophthalmoplegia, gastrointestinal dysmotility (often
CC       pseudoobstruction), diffuse leukoencephalopathy, cachexia,
CC       peripheral neuropathy, and myopathy. {ECO:0000269|PubMed:12177387,
CC       ECO:0000269|PubMed:9924029}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the thymidine/pyrimidine-nucleoside
CC       phosphorylase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TYMPID40397ch22q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M63193; AAA60043.1; -; mRNA.
DR   EMBL; AK225269; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U62317; AAB03344.2; -; Genomic_DNA.
DR   EMBL; BC018160; AAH18160.1; -; mRNA.
DR   EMBL; BC052211; AAH52211.1; -; mRNA.
DR   CCDS; CCDS14096.1; -. [P19971-1]
DR   CCDS; CCDS58811.1; -. [P19971-2]
DR   PIR; S03904; S03904.
DR   RefSeq; NP_001107227.1; NM_001113755.2. [P19971-1]
DR   RefSeq; NP_001107228.1; NM_001113756.2. [P19971-1]
DR   RefSeq; NP_001244917.1; NM_001257988.1. [P19971-1]
DR   RefSeq; NP_001244918.1; NM_001257989.1. [P19971-2]
DR   RefSeq; NP_001944.1; NM_001953.4. [P19971-1]
DR   UniGene; Hs.180903; -.
DR   UniGene; Hs.730607; -.
DR   PDB; 1UOU; X-ray; 2.11 A; A=12-482.
DR   PDB; 2J0F; X-ray; 2.31 A; A/B/C/D=1-482.
DR   PDB; 2WK5; X-ray; 2.99 A; A/B/C/D=1-482.
DR   PDB; 2WK6; X-ray; 2.50 A; A/B=1-482.
DR   PDBsum; 1UOU; -.
DR   PDBsum; 2J0F; -.
DR   PDBsum; 2WK5; -.
DR   PDBsum; 2WK6; -.
DR   ProteinModelPortal; P19971; -.
DR   SMR; P19971; -.
DR   BioGrid; 108219; 21.
DR   IntAct; P19971; 2.
DR   STRING; 9606.ENSP00000252029; -.
DR   BindingDB; P19971; -.
DR   ChEMBL; CHEMBL3106; -.
DR   DrugBank; DB01101; Capecitabine.
DR   DrugBank; DB00369; Cidofovir.
DR   DrugBank; DB00322; Floxuridine.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00432; Trifluridine.
DR   iPTMnet; P19971; -.
DR   PhosphoSitePlus; P19971; -.
DR   SwissPalm; P19971; -.
DR   BioMuta; TYMP; -.
DR   DMDM; 67477361; -.
DR   OGP; P19971; -.
DR   MaxQB; P19971; -.
DR   PaxDb; P19971; -.
DR   PeptideAtlas; P19971; -.
DR   PRIDE; P19971; -.
DR   DNASU; 1890; -.
DR   Ensembl; ENST00000252029; ENSP00000252029; ENSG00000025708. [P19971-1]
DR   Ensembl; ENST00000395678; ENSP00000379036; ENSG00000025708. [P19971-1]
DR   Ensembl; ENST00000395680; ENSP00000379037; ENSG00000025708. [P19971-1]
DR   Ensembl; ENST00000395681; ENSP00000379038; ENSG00000025708. [P19971-2]
DR   GeneID; 1890; -.
DR   KEGG; hsa:1890; -.
DR   UCSC; uc003bmb.7; human. [P19971-1]
DR   CTD; 1890; -.
DR   DisGeNET; 1890; -.
DR   GeneCards; TYMP; -.
DR   GeneReviews; TYMP; -.
DR   HGNC; HGNC:3148; TYMP.
DR   HPA; CAB002518; -.
DR   HPA; HPA000530; -.
DR   HPA; HPA001072; -.
DR   MalaCards; TYMP; -.
DR   MIM; 131222; gene.
DR   MIM; 603041; phenotype.
DR   neXtProt; NX_P19971; -.
DR   OpenTargets; ENSG00000025708; -.
DR   Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy.
DR   PharmGKB; PA162407502; -.
DR   eggNOG; ENOG410IIV8; Eukaryota.
DR   eggNOG; COG0213; LUCA.
DR   GeneTree; ENSGT00390000009250; -.
DR   HOGENOM; HOG000047313; -.
DR   HOVERGEN; HBG000082; -.
DR   InParanoid; P19971; -.
DR   KO; K00758; -.
DR   OMA; EVGCCIV; -.
DR   OrthoDB; EOG091G08UG; -.
DR   PhylomeDB; P19971; -.
DR   TreeFam; TF332198; -.
DR   BioCyc; MetaCyc:HS00442-MONOMER; -.
DR   BRENDA; 2.4.2.4; 2681.
DR   Reactome; R-HSA-73614; Pyrimidine salvage reactions.
DR   Reactome; R-HSA-73621; Pyrimidine catabolism.
DR   SABIO-RK; P19971; -.
DR   UniPathway; UPA00578; UER00638.
DR   EvolutionaryTrace; P19971; -.
DR   GeneWiki; ECGF1; -.
DR   GenomeRNAi; 1890; -.
DR   PRO; PR:P19971; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000025708; -.
DR   CleanEx; HS_TYMP; -.
DR   ExpressionAtlas; P19971; baseline and differential.
DR   Genevisible; P19971; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0008083; F:growth factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0004645; F:phosphorylase activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
DR   GO; GO:0016154; F:pyrimidine-nucleoside phosphorylase activity; IEA:InterPro.
DR   GO; GO:0009032; F:thymidine phosphorylase activity; IDA:CAFA.
DR   GO; GO:0016763; F:transferase activity, transferring pentosyl groups; EXP:Reactome.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; IMP:CAFA.
DR   GO; GO:0006206; P:pyrimidine nucleobase metabolic process; IEA:InterPro.
DR   GO; GO:0046135; P:pyrimidine nucleoside catabolic process; TAS:Reactome.
DR   GO; GO:0006213; P:pyrimidine nucleoside metabolic process; IDA:CAFA.
DR   GO; GO:0043097; P:pyrimidine nucleoside salvage; TAS:Reactome.
DR   GO; GO:1905333; P:regulation of gastric motility; IMP:CAFA.
DR   GO; GO:0031641; P:regulation of myelination; IMP:CAFA.
DR   GO; GO:0051969; P:regulation of transmission of nerve impulse; IMP:CAFA.
DR   Gene3D; 3.40.1030.10; -; 1.
DR   InterPro; IPR000312; Glycosyl_Trfase_fam3.
DR   InterPro; IPR017459; Glycosyl_Trfase_fam3_N_dom.
DR   InterPro; IPR013102; PYNP_C.
DR   InterPro; IPR018090; Pyrmidine_PPas_bac/euk.
DR   InterPro; IPR017872; Pyrmidine_PPase_CS.
DR   InterPro; IPR000053; Thymidine/pyrmidine_PPase.
DR   PANTHER; PTHR10515; PTHR10515; 1.
DR   Pfam; PF02885; Glycos_trans_3N; 1.
DR   Pfam; PF00591; Glycos_transf_3; 1.
DR   Pfam; PF07831; PYNP_C; 1.
DR   PIRSF; PIRSF000478; TP_PyNP; 1.
DR   SMART; SM00941; PYNP_C; 1.
DR   SUPFAM; SSF47648; SSF47648; 1.
DR   SUPFAM; SSF52418; SSF52418; 1.
DR   SUPFAM; SSF54680; SSF54680; 1.
DR   TIGRFAMs; TIGR02644; Y_phosphoryl; 1.
DR   PROSITE; PS00647; THYMID_PHOSPHORYLASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Chemotaxis;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disease mutation; Glycosyltransferase;
KW   Growth factor; Phosphoprotein; Polymorphism;
KW   Progressive external ophthalmoplegia; Reference proteome; Repeat;
KW   Transferase.
FT   PROPEP        1     10
FT                                /FTId=PRO_0000035874.
FT   CHAIN        11    482       Thymidine phosphorylase.
FT                                /FTId=PRO_0000035875.
FT   REPEAT      265    279       R-V-A-A-A-L-X(5,6)-L-G-R.
FT   REPEAT      329    342       R-V-A-A-A-L-X(5,6)-L-G-R.
FT   REPEAT      393    401       R-A-L-X-X-A-L-V-L.
FT   REPEAT      453    461       R-A-L-X-X-A-L-V-L.
FT   BINDING     116    116       Substrate.
FT   BINDING     202    202       Substrate.
FT   BINDING     217    217       Substrate.
FT   BINDING     221    221       Substrate.
FT   MOD_RES       6      6       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q5FVR2}.
FT   VAR_SEQ     386    386       D -> DAPLPA (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_045556.
FT   VARIANT      44     44       R -> Q (in MTDPS1; dbSNP:rs28931613).
FT                                {ECO:0000269|PubMed:12177387}.
FT                                /FTId=VAR_016777.
FT   VARIANT     145    145       G -> R (in MTDPS1; dbSNP:rs121913037).
FT                                {ECO:0000269|PubMed:9924029}.
FT                                /FTId=VAR_007643.
FT   VARIANT     153    153       G -> S (in MTDPS1; dbSNP:rs121913038).
FT                                {ECO:0000269|PubMed:9924029}.
FT                                /FTId=VAR_007644.
FT   VARIANT     222    222       K -> R (in MTDPS1; dbSNP:rs149977726).
FT                                {ECO:0000269|PubMed:9924029}.
FT                                /FTId=VAR_007645.
FT   VARIANT     289    289       E -> A (in MTDPS1; dbSNP:rs121913036).
FT                                {ECO:0000269|PubMed:9924029}.
FT                                /FTId=VAR_007646.
FT   VARIANT     397    398       Missing (in MTDPS1).
FT                                {ECO:0000269|PubMed:9924029}.
FT                                /FTId=VAR_007647.
FT   VARIANT     471    471       S -> L (in dbSNP:rs11479).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2467210}.
FT                                /FTId=VAR_007648.
FT   MUTAGEN     199    199       Y->A: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:19555658}.
FT   MUTAGEN     199    199       Y->F: Reduced catalytic activity.
FT                                {ECO:0000269|PubMed:19555658}.
FT   MUTAGEN     199    199       Y->L: Reduced catalytic activity.
FT                                {ECO:0000269|PubMed:19555658}.
FT   CONFLICT    195    195       D -> E (in Ref. 5; AAH18160).
FT                                {ECO:0000305}.
FT   HELIX        36     44       {ECO:0000244|PDB:1UOU}.
FT   HELIX        51     63       {ECO:0000244|PDB:1UOU}.
FT   HELIX        68     81       {ECO:0000244|PDB:1UOU}.
FT   HELIX        85     96       {ECO:0000244|PDB:1UOU}.
FT   HELIX       106    111       {ECO:0000244|PDB:1UOU}.
FT   STRAND      112    118       {ECO:0000244|PDB:1UOU}.
FT   HELIX       125    134       {ECO:0000244|PDB:1UOU}.
FT   TURN        135    137       {ECO:0000244|PDB:1UOU}.
FT   STRAND      139    143       {ECO:0000244|PDB:1UOU}.
FT   HELIX       154    158       {ECO:0000244|PDB:1UOU}.
FT   HELIX       170    180       {ECO:0000244|PDB:1UOU}.
FT   STRAND      181    185       {ECO:0000244|PDB:1UOU}.
FT   STRAND      189    192       {ECO:0000244|PDB:1UOU}.
FT   HELIX       193    204       {ECO:0000244|PDB:1UOU}.
FT   HELIX       211    224       {ECO:0000244|PDB:1UOU}.
FT   STRAND      228    236       {ECO:0000244|PDB:1UOU}.
FT   STRAND      240    244       {ECO:0000244|PDB:2J0F}.
FT   HELIX       245    261       {ECO:0000244|PDB:1UOU}.
FT   STRAND      266    272       {ECO:0000244|PDB:1UOU}.
FT   STRAND      280    283       {ECO:0000244|PDB:1UOU}.
FT   HELIX       284    294       {ECO:0000244|PDB:1UOU}.
FT   HELIX       300    316       {ECO:0000244|PDB:1UOU}.
FT   STRAND      319    322       {ECO:0000244|PDB:2J0F}.
FT   HELIX       323    335       {ECO:0000244|PDB:1UOU}.
FT   HELIX       338    349       {ECO:0000244|PDB:1UOU}.
FT   HELIX       354    362       {ECO:0000244|PDB:1UOU}.
FT   HELIX       365    371       {ECO:0000244|PDB:1UOU}.
FT   STRAND      376    382       {ECO:0000244|PDB:1UOU}.
FT   STRAND      387    392       {ECO:0000244|PDB:1UOU}.
FT   HELIX       394    405       {ECO:0000244|PDB:1UOU}.
FT   STRAND      409    412       {ECO:0000244|PDB:2WK5}.
FT   STRAND      420    423       {ECO:0000244|PDB:1UOU}.
FT   STRAND      436    446       {ECO:0000244|PDB:1UOU}.
FT   HELIX       449    458       {ECO:0000244|PDB:1UOU}.
FT   STRAND      459    464       {ECO:0000244|PDB:1UOU}.
FT   STRAND      475    477       {ECO:0000244|PDB:1UOU}.
SQ   SEQUENCE   482 AA;  49955 MW;  0652FA0B8F3BDE28 CRC64;
     MAALMTPGTG APPAPGDFSG EGSQGLPDPS PEPKQLPELI RMKRDGGRLS EADIRGFVAA
     VVNGSAQGAQ IGAMLMAIRL RGMDLEETSV LTQALAQSGQ QLEWPEAWRQ QLVDKHSTGG
     VGDKVSLVLA PALAACGCKV PMISGRGLGH TGGTLDKLES IPGFNVIQSP EQMQVLLDQA
     GCCIVGQSEQ LVPADGILYA ARDVTATVDS LPLITASILS KKLVEGLSAL VVDVKFGGAA
     VFPNQEQARE LAKTLVGVGA SLGLRVAAAL TAMDKPLGRC VGHALEVEEA LLCMDGAGPP
     DLRDLVTTLG GALLWLSGHA GTQAQGAARV AAALDDGSAL GRFERMLAAQ GVDPGLARAL
     CSGSPAERRQ LLPRAREQEE LLAPADGTVE LVRALPLALV LHELGAGRSR AGEPLRLGVG
     AELLVDVGQR LRRGTPWLRV HRDGPALSGP QSRALQEALV LSDRAPFAAP SPFAELVLPP
     QQ
//
